Bicara Therapeutics Inc

BCAX is in Stage 3 distribution, characterized by a blow-off top and immediate rejection, with short-term momentum turned down under the 9/21 EMAs. The medium-term tradable stance is bearish, favoring sell-side interaction on rallies into the short-EMA zone, while the long-term uptrend remains intact above the 200 DMA. Key risks include a failure to sustain selling pressure and a reclaim of short-term EMAs, which would invalidate the bearish bias.

• ↑Fisera delivered median overall survival of 21.3 months vs 6.7 months standard care
• ↑$539.8 M cash balance provides funding through H1 2029
• ↓Operating expenses jumped 45% YoY to $112.8 M, elevating leverage risk